26 results
424B3
COYA
Coya Therapeutics Inc
24 Jun 24
Prospectus supplement
5:31pm
is driven by the chronic inflammatory environment and high levels of oxidative stress commonly observed in certain diseases. Further, the degree of Treg
8-K
EX-99.1
COYA
Coya Therapeutics Inc
20 May 24
Coya Therapeutics Announces $5 Million Strategic
5:00pm
2 trial in FTD.
“Inflammation has emerged as a promising novel pathway for chronic neurological diseases like FTD. A combination drug, like COYA 302
424B3
pdze 6s8axq78e
16 Jan 24
Prospectus supplement
4:06pm
S-3
h7zxhyv6k9q4r
4 Jan 24
Shelf registration
4:46pm
8-K
EX-99.1
nscfw3o3wa8ho19wu
6 Dec 23
Entry into a Material Definitive Agreement
7:30am
DEF 14A
kdhsr xw67
19 May 23
Definitive proxy
4:31pm
424B4
7op8bzjjx f0
12 May 23
Prospectus supplement with pricing info
4:16pm
10-Q
9owh9mc 34xgvpkjqdb
10 May 23
Quarterly report
7:14am
10-Q
EX-10.1
hznd0wb
10 May 23
Quarterly report
7:14am
POS AM
46kal t2z06n
8 May 23
Prospectus update (post-effective amendment)
9:00am
10-K
nlcrd6u09l904 cshtd
29 Mar 23
Annual report
4:08pm
424B4
ky7pm93c uxt0rc64a
30 Dec 22
Prospectus supplement with pricing info
4:17pm